PMID- 28523483
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220318
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 8
IP  - 4
DP  - 2017 Aug
TI  - Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 
      Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The 
      Netherlands.
PG  - 753-765
LID - 10.1007/s13300-017-0266-3 [doi]
AB  - INTRODUCTION: Insulin degludec/liraglutide (IDegLira) is the first basal insulin 
      and glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a single pen injection 
      device, and a once-daily treatment option for patients with type 2 diabetes 
      mellitus (T2DM) who are uncontrolled on basal insulin and require treatment 
      intensification. The objective of this analysis was to evaluate the long-term 
      cost-effectiveness of IDegLira versus basal-bolus therapy (insulin glargine 
      U100 + 3x daily insulin aspart) for patients with T2DM uncontrolled on basal 
      insulin [HbA(1c) >53 mmol/mol (>7%)] in the Netherlands. METHODS: 
      Cost-effectiveness analysis was performed using the validated IMS CORE Diabetes 
      Model from a healthcare payer perspective. Outcomes were modeled over patient 
      lifetimes in a cohort with baseline characteristics from the DUAL II trial. 
      Treatment effect data were sourced from a statistical indirect comparison (pooled 
      analysis) of IDegLira with basal-bolus therapy. RESULTS: Treatment with IDegLira 
      resulted in mean increases in quality-adjusted life expectancy of 0.43 
      quality-adjusted life years versus basal-bolus therapy. Improved clinical 
      outcomes resulted from fewer diabetes-related complications and a delayed time to 
      their onset. IDegLira was associated with lower costs of EUR 4679 versus 
      basal-bolus therapy, a result of lower pharmacy costs and avoided 
      diabetes-related complications. Thus, IDegLira was dominant, i.e., both more 
      effective and less costly than basal-bolus therapy. CONCLUSIONS: IDegLira is an 
      effective treatment option to improve glycemic control without incurring an 
      increased risk of hypoglycemia or weight gain. This analysis suggests that 
      IDegLira is cost-effective versus basal-bolus therapy in patients with T2DM who 
      are uncontrolled on basal insulin in the Netherlands. FUNDING: Novo Nordisk.
FAU - Hunt, Barnaby
AU  - Hunt B
AD  - Ossian Health Economics and Communications, Baumleingasse 20, 4051, Basel, 
      Switzerland.
FAU - Glah, Divina
AU  - Glah D
AD  - Novo Nordisk Ltd, Gatwick, West Sussex, UK.
FAU - van der Vliet, Maarten
AU  - van der Vliet M
AD  - Novo Nordisk BV, Alphen aan den Rijn, The Netherlands. mtvt@novonordisk.com.
LA  - eng
PT  - Journal Article
DEP - 20170518
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC5544604
OTO - NOTNLM
OT  - GLP-1 analogs
OT  - HbA1c
OT  - Hypoglycemia
OT  - Insulin analogs
OT  - Type 2 diabetes
EDAT- 2017/05/20 06:00
MHDA- 2017/05/20 06:01
PMCR- 2017/05/18
CRDT- 2017/05/20 06:00
PHST- 2017/04/05 00:00 [received]
PHST- 2017/05/20 06:00 [pubmed]
PHST- 2017/05/20 06:01 [medline]
PHST- 2017/05/20 06:00 [entrez]
PHST- 2017/05/18 00:00 [pmc-release]
AID - 10.1007/s13300-017-0266-3 [pii]
AID - 266 [pii]
AID - 10.1007/s13300-017-0266-3 [doi]
PST - ppublish
SO  - Diabetes Ther. 2017 Aug;8(4):753-765. doi: 10.1007/s13300-017-0266-3. Epub 2017 
      May 18.